

Lapatinib

Catalog No: tcsc0036



Available Sizes

Size: 50mg

Size: 100mg

Size: 500mg

Size: 1g

Size: 2g

Size: 5g



Specifications

CAS No:

231277-92-2

Formula:

$C_{29}H_{26}ClFN_4O_4S$

Pathway:

JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Autophagy

Target:

EGFR;EGFR;Autophagy

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 39 mg/mL (67.12 mM)

Alternative Names:

GW572016

Observed Molecular Weight:

581.06


Product Description

Lapatinib is a potent **EGFR** and **ErbB2** inhibitor with **IC₅₀** of 10.2 and 9.8 nM, respectively.

IC50 & Target: IC50: 10.2 nM (EGFR), 9.8 nM (ErbB2)^[1]

In Vitro: The IC₅₀ of Lapatinib (GW2016) values for inhibition of enzyme activity are generated by measuring inhibition of phosphorylation of a peptide substrate. With the exception of ErbB-4 (IC₅₀, 367 nM), Lapatinib is >300-fold selective for EGFR and ErbB-2 over other kinases tested^[1]. IC₅₀ values of Lapatinib (GW2016) for BT474, SKBR3, EFM192A, HCC1954, MDAMB453 and MDAMB231 cells is 36±15.1 nM, 80±17.3 nM, 193±66.5 nM, 416.6±180 nM, 6.08±0.825 μM and 7.46±0.102 μM, respectively. Treatment with Lapatinib results in IC₅₀ values of ≤ 0.16 μM on the EGFR- and the ErbB-2-overexpressing tumor cell lines^[2].

In Vivo: Lapatinib (GW2016) is potent at inhibiting the growth of BT474 and HN5 human tumor xenografts. A dose-responsive inhibition of both models occurred on treatment of tumor-bearing mice with 30 and 100 mg/kg Lapatinib orally, twice daily. Complete inhibition of tumor growth is seen at the 100 mg/kg dose. At this dose, there is [1]. Lapatinib (100 mg/kg/day, oral gavage) induces severe oxidative damage in the cardiac tissue of rat^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!